MIRA MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About MIRA Pharmaceuticals (NASDAQ: MIRA)
›
MIRA Pharmaceuticals (NASDAQ: MIRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.
The shares were at 0.3683 USD on 19 November 2026, down 74.4% over 52 weeks. Its 52-week range is 0.3400 USD to 1.690 USD: the price is 78.2% below the high and 8.3% above the low.
At a market capitalisation of 15.48M USD, it trades at 36.8 times trailing earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a premium of 41% for MIRA.
MIRA Pharmaceuticals reports return on equity of -100.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 8.11M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.